OTC · CIK 0001870404
CERO CERO THERAPEUTICS HOLDINGS, INC.
Insider trading from SEC Form 4. Last filing Apr 21, 2026. Close $0.01 on Oct 9, 2026, +13% from the 52-week low and -100% from the high.
CERO THERAPEUTICS HOLDINGS, INC. (CERO) has 41 SEC Form 4 filings on file from 11 insiders, the latest filed on Apr 21, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at CERO. The newest: YK Bioventures Opportunities GP I, LLC (10% owner) sold $400k of stock on Dec 11, 2024, filed Dec 13, 2024, scored 38 (weak).
CERO closed at $0.01 on Oct 9, 2026, 13% above its 52-week low and 100% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at CERO THERAPEUTICS HOLDINGS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | YK Bioventures Opportunities GP I, LLC owner sell | $400k 5,957,250 shares | -31% | - | |
| 33Weak | YK Bioventures Opportunities GP I, LLC owner sell | $383k 3,658,364 shares | -16% | - | |
| 19Weak | Stuart M Sloan owner sell | $56k 532,486 shares | -2% | - | |
| 31Weak | YK Bioventures Opportunities GP I, LLC owner sell | $325k 3,250,000 shares | -13% | - |
Transactions
Every row filed, 49 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | Eric Francois director | AGrant or award Stock Option (Right to Buy)derivative | +1,823,278 | $0.00 | $0 | 1,823,278 | Apr 21, 2026 |
| Jan 7, 2026 | Brian G Atwood director | AGrant or award Stock Option (Right to Buy)derivative | +1,612,099 | $0.00 | $0 | 1,612,099 | Jan 9, 2026 |
| Jan 7, 2026 | Michael Byrnes director | AGrant or award Stock Option (Right to Buy)derivative | +690,900 | $0.00 | $0 | 690,900 | Jan 9, 2026 |
| Jan 7, 2026 | Kristen Pierce Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,612,099 | $0.00 | $0 | 1,612,099 | Jan 9, 2026 |
| Jan 7, 2026 | Shami Patel director | AGrant or award Stock Option (Right to Buy)derivative | +690,900 | $0.00 | $0 | 690,900 | Jan 9, 2026 |
| Jan 7, 2026 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +690,900 | $0.00 | $0 | 690,900 | Jan 9, 2026 |
| Jan 7, 2026 | Andrew Albert Kucharchuk Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,162,099 | $0.00 | $0 | 1,162,099 | Jan 9, 2026 |
| Jan 7, 2026 | Lindsey Rolfe director | AGrant or award Stock Option (Right to Buy)derivative | +690,900 | $0.00 | $0 | 690,900 | Jan 9, 2026 |
| Jan 7, 2026 | Christopher B Ehrlich Chairman and CEO | AGrant or award Stock Option (Right to Buy)derivative | +4,530,997 | $0.00 | $0 | 4,530,997 | Jan 9, 2026 |
| May 30, 2025 | Andrew Albert Kucharchuk Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +152,500 | $0.00 | $0 | 152,500 | Jun 2, 2025 |
| May 30, 2025 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +9,326 | $0.00 | $0 | 9,326 | Jun 2, 2025 |
| May 30, 2025 | Lindsey Rolfe director | AGrant or award Stock Option (Right to Buy)derivative | +9,326 | $0.00 | $0 | 9,326 | Jun 2, 2025 |
| May 30, 2025 | Shami Patel director | AGrant or award Stock Option (Right to Buy)derivative | +11,693 | $0.00 | $0 | 11,693 | Jun 2, 2025 |
| May 30, 2025 | Christopher B Ehrlich Chairman and CEO | AGrant or award Stock Option (Right to Buy)derivative | +61,843 | $0.00 | $0 | 61,842 | Jun 2, 2025 |
| May 30, 2025 | Kristen Pierce Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +154,841 | $0.00 | $0 | 154,841 | Jun 2, 2025 |
| May 30, 2025 | Michael Byrnes director | AGrant or award Stock Option (Right to Buy)derivative | +9,326 | $0.00 | $0 | 9,326 | Jun 2, 2025 |
| May 30, 2025 | Brian G Atwood director | AGrant or award Stock Option (Right to Buy)derivative | +122,549 | $0.00 | $0 | 122,549 | Jun 2, 2025 |
| Mar 31, 2025 | Brian G Atwood director | MOption exercise Common Stockindirect: See Footnote | +294,460 | $0.00 | $29 | 490,534 | Apr 4, 2025 |
| Mar 31, 2025 | Brian G Atwood director | MOption exercise Pre-Funded Warrantderivative | +294,460 | $0.00 | $29 | 11,660 | Apr 4, 2025 |
| Mar 4, 2025 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +17,923 | $0.00 | $0 | 17,923 | Mar 6, 2025 |
| Mar 4, 2025 | Lindsey Rolfe director | AGrant or award Stock Option (Right to Buy)derivative | +17,923 | $0.00 | $0 | 17,923 | Mar 6, 2025 |
| Mar 4, 2025 | Shami Patel director | AGrant or award Stock Option (Right to Buy)derivative | +14,936 | $0.00 | $0 | 14,936 | Mar 6, 2025 |
| Mar 4, 2025 | Michael Byrnes director | AGrant or award Stock Option (Right to Buy)derivative | +17,923 | $0.00 | $0 | 17,923 | Mar 6, 2025 |
| Mar 4, 2025 | Brian G Atwood director | AGrant or award Stock Option (Right to Buy)derivative | +14,936 | $0.00 | $0 | 14,936 | Mar 6, 2025 |
| Mar 4, 2025 | Christopher B Ehrlich Chairman and CEO | AGrant or award Stock Option (Right to Buy)derivative | +119,486 | $0.00 | $0 | 119,486 | Mar 6, 2025 |
| Feb 24, 2025 | Brian G Atwood director | AGrant or award Stock Option (Right to Buy)derivative | +254,000 | $0.00 | $0 | 508,000 | Feb 26, 2025 |
| Feb 24, 2025 | Michael Byrnes director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 255,000 | Feb 26, 2025 |
| Feb 24, 2025 | Christopher B Ehrlich Chairman and CEO | AGrant or award Stock Option (Right to Buy)derivative | +1,275,000 | $0.00 | $0 | 2,550,000 | Feb 26, 2025 |
| Feb 24, 2025 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 255,000 | Feb 26, 2025 |
| Feb 24, 2025 | Shami Patel director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 255,000 | Feb 26, 2025 |
| Feb 24, 2025 | Lindsey Rolfe director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 255,000 | Feb 26, 2025 |
| Feb 7, 2025 | Brian G Atwood director | AGrant or award Pre-Funded Warrantderivative | +306,120 | $0.00 | $31 | 306,120 | Feb 7, 2025 |
| Feb 7, 2025 | Brian G Atwood director | AGrant or award Pre-Funded Warrantderivativeindirect: By GVN, LLC | +204,080 | $0.00 | $20 | 204,080 | Feb 7, 2025 |
| Feb 7, 2025 | Brian G Atwood director | AGrant or award Warrant to Purchase Shares of Common Stockderivative | +306,120 | $1.96 | $600k | 306,120 | Feb 7, 2025 |
| Feb 7, 2025 | Brian G Atwood director | AGrant or award Warrant to Purchase Shares of Common Stockderivativeindirect: By GVN, LLC | +204,080 | $1.96 | $400k | 204,080 | Feb 7, 2025 |
| Dec 11, 2024 | YK Bioventures Opportunities GP I, LLC owner | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,343,801 | $0.08 | $108k | 17,618,618 | Dec 13, 2024 |
| Dec 12, 2024 | YK Bioventures Opportunities GP I, LLC owner | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,614,541 | $0.07 | $113k | 16,004,077 | Dec 13, 2024 |
| Dec 13, 2024 | YK Bioventures Opportunities GP I, LLC owner | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -2,998,908 | $0.06 | $180k | 13,005,169 | Dec 13, 2024 |
| Dec 6, 2024 | YK Bioventures Opportunities GP I, LLC owner | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,236,874 | $0.12 | $148k | 21,383,909 | Dec 10, 2024 |
| Dec 9, 2024 | YK Bioventures Opportunities GP I, LLC owner | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -850,543 | $0.11 | $94k | 20,533,366 | Dec 10, 2024 |
| Dec 10, 2024 | YK Bioventures Opportunities GP I, LLC owner | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,570,947 | $0.09 | $141k | 18,962,419 | Dec 10, 2024 |
| Dec 2, 2024 | Brian G Atwood director | AGrant or award Stock Option (Right to Buy)derivative | +254,000 | $0.00 | $0 | 254,000 | Dec 4, 2024 |
| Dec 2, 2024 | Michael Byrnes director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 127,500 | Dec 4, 2024 |
| Dec 2, 2024 | Shami Patel director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 127,500 | Dec 4, 2024 |
| Dec 2, 2024 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 127,500 | Dec 4, 2024 |
| Dec 2, 2024 | Lindsey Rolfe director | AGrant or award Stock Option (Right to Buy)derivative | +127,500 | $0.00 | $0 | 127,500 | Dec 4, 2024 |
| Dec 2, 2024 | Christopher B Ehrlich Chairman and CEO | AGrant or award Stock Option (Right to Buy)derivative | +1,275,000 | $0.00 | $0 | 1,275,000 | Dec 4, 2024 |
| Sep 25, 2024 | Stuart M Sloan owner | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By SMS Revocable Trust | -532,486 | $0.10 | $56k | 21,067,956 | Nov 20, 2024 |
| Oct 10, 2024 | YK Bioventures Opportunities GP I, LLC owner | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -3,250,000 | $0.10 | $325k | 22,620,783 | Nov 14, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Brian G Atwooddirector
- Michael Byrnesdirector
- Christopher B EhrlichChairman and CEO
- Eric Francoisdirector
- Andrew Albert KucharchukChief Financial Officer
- Kathleen Laportedirector
- Shami Pateldirector
- Kristen PierceChief Development Officer
- Lindsey Rolfedirector
- Stuart M Sloanowner
- YK Bioventures Opportunities GP I, LLCowner
Questions about CERO
Answered from the filings on this page, as of the latest one.
Are insiders buying CERO?
No. In the last 90 days no insider at CERO THERAPEUTICS HOLDINGS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CERO on the open market?
YK Bioventures Opportunities GP I, LLC (10% owner) sold $400k of CERO on Dec 11, 2024 and filed the Form 4 on Dec 13, 2024. InsiderTell scored 38 (weak).
How many insiders file Form 4 at CERO THERAPEUTICS HOLDINGS, INC.?
11 people have filed a Form 4 at CERO THERAPEUTICS HOLDINGS, INC., among them Brian G Atwood (director), Michael Byrnes (director), Christopher B Ehrlich (Chairman and CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.